Next Article in Journal / Special Issue
What Has 30 Years of HIV Vaccine Research Taught Us?
Previous Article in Journal / Special Issue
Developing Combined HIV Vaccine Strategies for a Functional Cure
Vaccines 2013, 1(4), 497-512; doi:10.3390/vaccines1040497
Review

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens

The Sir William Dunn School of Pathology, The University of Oxford, South Parks Road, Oxford OX13RE, UK
Received: 6 September 2013 / Revised: 11 October 2013 / Accepted: 12 October 2013 / Published: 28 October 2013
(This article belongs to the Special Issue HIV Vaccines)
View Full-Text   |   Download PDF [580 KB, uploaded 28 October 2013]   |   Browse Figures
SciFeed

Abstract

The HIV-1 envelope glycoprotein spike is the target of neutralizing antibody attack, and hence represents the only relevant viral antigen for antibody-based vaccine design. Various approaches have been attempted to recapitulate Env in membrane-anchored and soluble forms, and these will be discussed here in the context of recent successes and challenges still to be overcome.
Keywords: HIV-1; vaccine; neutralizing antibodies; envelope glycoproteins; trimer HIV-1; vaccine; neutralizing antibodies; envelope glycoproteins; trimer
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Sattentau, Q.J. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines 2013, 1, 497-512.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert